Onset rate and intensity of signs of organophosphate poisoning related to paraoxon dose and survival in rats

Žana M. Maksimović1,2, Dajana Duka3, Nataša Bednarčuk3, Ranko Škrbić2,4, Miloš P. Stojiljković2,4

1Primary Healthcare Centre, Modriča, the Republic of Srpska, Bosnia and Herzegovina
2University of Banja Luka, Faculty of Medicine, Centre for Biomedical Research, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina
3University of Banja Luka, Faculty of Medicine, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina
4University of Banja Luka, Faculty of Medicine, Department of Pharmacology, Toxicology and Clinical Pharmacology, Banja Luka, the Republic of Srpska, Bosnia and Herzegovina

Abstract:
Introduction: Organophosphorus compounds (OP) bind to acetylcholinesterase (AChE) and inactivate it. In the synaptic cleft, undestroyed and accumulated acetylcholine produce the acute cholinergic effects. The aim of this study was to determine the frequency, speed of onset and intensity of certain signs of paraoxon poisoning depending on dose and outcome of poisoning. Methods: The study was conducted in adult Wistar rats. The median lethal dose (LD50) of paraoxon as well as protective ratio (PR) of atropine (10 mg/kg intramuscularly) was determined. Clinical signs of poisoning were observed: fasciculations, tremor, seizures, ataxia, piloerection, lacrimation, exophthalmos, bizarre/stereotypic behavior and dyspnoea. The time from paraoxon injection to the first appearance of the sign of poisoning was recorded as well as the intensity of poisoning with evaluation at 10 time intervals throughout the 4 h observational period. Results: The LD50 of paraoxon was 0.33 mg/kg (subcutaneously) and PR of atropine was 2.73. Dose-dependent, piloerection occurred more often (p = 0.009) and at higher intensity (p = 0.016) at higher doses. Fasciculations, tremor, seizures and ataxia occurred significantly earlier at higher doses of paraoxon (p = 0.015, 0.002, 0.021 and 0.016, respectively), as well as the intensity of seizure, tremor and fasciculation. Piloerection (p = 0.002) and seizures occurred more frequently (p = 0.009) in non-survivors. Fasciculations, tremor, seizures and ataxia occurred significantly earlier and at higher intensity in non-survivors (p < 0.001, for all parameters), as well as dyspnoea (p = 0.009 and p = 0.048). In atropine-protected rats, nicotinic effects persevered, so they were the prognostic parameter of the severity of the poisoning. Conclusion: Seizures and fasciculations followed by tremor were strong prognostic parameters of the probability of lethal outcome of paraoxon poisoning. Also, the mentioned poisoning signs were with their intensity and speed of occurrence in a clear positive correlation with the administered dose of paraoxon. Even at high doses of paraoxon, atropine blocked the muscarinic (but not nicotinic) effects and somewhat mitigated the CNS toxic effects.

Keywords: organophosphate; acetylcholinesterase inhibitor; paraoxon; insecticide; poisoning; atropine

INTRODUCTION
In the body, organophosphorus compound (OPC) binds to the serine group of the enzyme acetylcholinesterase (AChE, EC 3.1.1.7), phosphorylates it and creates a stable covalent bond with it [1]. By binding to it, AChE becomes inactive and cannot perform its function, which is the breakdown of acetylcholine in the synaptic cleft [2]. Accumulated acetylcholine (ACh) stimulates various postsynaptic cholinergic receptors and exhibits its acute cholinergic effects: muscarinic (bronchorrhoea, bronchoconstriction, bradycardia, hypotension, miosis, hypersalivation, lacrimation, nausea, vomiting, increased motility of the bowels and of the bladder), nicotinic (mydriasis, tachycardia, hypertension, fibrillation, fasciculation and necrosis of skeletal muscles) and central (tremor, convulsions, motor incoordination, respiratory depression and coma) [3]. Besides acute cholinergic crisis, OP poisoning can manifest itself as intermediate syndrome, organophosphate-induced delayed neuropathy (OPIDN) and chronic organophosphate-induced neuropsychiatric disorder due to long-term low-level exposure [4].
The OP-AChE bond does not spontaneously dissociate (hydrolyses) in the body, which is why OPs are called irreversible AChE inhibitors. The bond can be separated using AChE reactivators, so-called oximes, which are causal antidotes in OP poisonings [5]. Unfortunately, the diversity of OPs makes oximes insufficiently universal and effective antidotes [6]. An additional limitation of its efficacy is the process of dealkylation (so-called “ageing”) through which the OP-AChE bond passes, after which it is not possible to separate OP and AChE [7]. Ageing in some OPCs like the nerve agent soman is measured in minutes, while in organophosphorus insecticide (OPI) it is mostly measured in days [8].

Although oximes are the only causal antidotes, their insufficient efficacy, especially in clinical practice, makes anticholinergic drugs still the main antidotes in OP poisoning. The most commonly used and most available anticholinergic drug is atropine, which blocks the muscarinic effects of OP poisoning, but not the nicotinic ones [9]. The contribution to the protective effect of atropine is its lipophilicity, ie the ability to penetrate the CNS. There is an assumption whether more lipophilic anticholinergics would have better protection against OP poisoning than atropine. However, there are no clinical studies to corroborate this notion.

In addition to atropine and oximes (pralidoxime and obidoxime), anticonvulsants, primarily diazepam and midazolam, are also used in the treatment of OP poisoning. Anticonvulsants are important, especially when the fact that the fatal outcome in OP poisoning most often occurs due to seizures and respiratory failure is taken into account [10][4].

Although most developed countries have banned the use of the most toxic pesticides, OPI poisonings, especially the intentional ones, are still common, especially in undeveloped and developing countries [11][12]. Unfortunately, due to the high toxicity of OPCs, they continue to be abused for terrorist purposes and as nerve agents (tabun, sarin, soman and VX) [13]. Paraoxon (diethyl (4-nitrophenyl) phosphate) is the active metabolite of the OPI parathion [14]. Due to its toxicity and chemical characteristics, it serves as a good experimental tool in the field of research of toxicity of nerve agents.

The aim of the study was to determine whether increasing doses of paraoxon affect the rate and intensity of signs of poisoning with an AChE inhibitor. The aim was also to determine whether the speed of onset and intensity of the appearance of certain signs of poisoning can be a prognostic sign of the fatal outcome of poisoning. In addition, the goal was to determine how clinical signs are manifested at high (> LD∞) doses of paraoxon in the presence of an antidote (atropine).

**METHODS**

**Animals**

The study was conducted in adult male and female Wistar rats, weighing 200-240 g, purchased from Faculty of Natural Sciences and Mathematics, University of Banja Luka, the Republic of Srpska. The animals had access to food and water *ad libitum*. The room temperature was maintained at 20-22 °C, with a 12 h light and dark cycle. The study was approved by Ethics Committee for the Protection and Welfare of Experimental Animals in Biomedical Research, Faculty of Medicine, University of Banja Luka (Decision No 18/1/20). During the entire experiment, the "Guiding principles in the care of and use of laboratory animals" have been observed.

**Chemicals**

Paraoxon was purchased from Sigma Aldrich, St Louis, MO, USA. Application volume of the chemical was 1 mL/kg. Paraoxon was injected subcutaneously (sc) into the abdominal region, while atropine was administered intramuscularly (im) into the right thigh. Stock solution of paraoxon (100 mg/mL) was dissolved in isopropyl alcohol. Final dilution for sc administration was made from saline (0.9% NaCl) before injection. Atropine sulphate monohydrate was dissolved in saline up to the concentration of 10 mg/mL.

**Study design**

In these experiments, lethality of paraoxon and an antidote potential of atropine was based on the 24 h survival.

**a) Paraoxon and saline**

Increasing doses of paraoxon were administered sc. Each group consisted of 6 rats and doses were determined by the “up and down” method (doses were: 0.2, 0.3, 0.35, 0.4 mg/kg). One minute after paraoxon injection, rats were injected with 1 mL/kg saline im. Based on the 24 h lethality, median lethal dose (LD50) was calculated.

**b) Paraoxon and atropine**

Increasing doses of paraoxon were administered sc (doses were: 0.6, 0.9, 1.2 mg/kg). Each group consisted...
of 6 rats and doses were determined by the “up and down” method. One minute after the injection of paraoxon, the rats were injected with 10 mg/kg of atropine im. The outcome was protective ratio (PR) ie, ratio of LD_{50} in protected and in unprotected rats.

c) Clinical signs of poisoning

The following clinical signs of poisoning were observed: fasciculations, tremor, seizures, ataxia, piloerection, lacrimation, exophthalmos, bizzare/stereotypic behaviour, dyspnoea. The time from paraoxon injection to the appearance of the sign of poisoning was recorded. The intensity of poisoning was recorded as: 0 - absent, 1 - mild / moderate, 2 - severe. To analyse the intensity of symptoms throughout the observed period (4 h), ToxScore was introduced, as a parameter that summed the intensity of each sign in all time intervals. TotToxScore was a measure that represented the sum of all ToxScore for one animal.

Statistics

The LD_{50} values were computed by means of the Pharm/PCS statistical software, according to the Litchfield and Wilcoxon (1949) [15]. IBM SPSS 21.0 software was used for other statistical procedures. After the normality of data distribution was analysed (Kolmogorov–Smirnov test), the appropriate parametric / nonparametric test was used (Student t-test / Mann-Whitney U test, One Way ANOVA / Kruskal-Wallis test) as well as Chi-Squared test for categorical data.

RESULTS

Paraoxon

a) Dose

The LD_{50} of paraoxon was 0.33 mg/kg sc (95% CI: 0.31 - 0.36). In all rats, death occurred in the first hour of poisoning (mean ± SD: 19.19 ± 6.19, 95% CI: 16.37 - 22.01).

Fasciculations occurred in 85.71% of all rats, piloerection in 50.00%, exophthalmos in 95.23%, lacrimation in 54.76%, tremor in 97.62%, seizures in 83.33%, ataxia in 66.67%, stereotypic behaviour in 69.05% and dyspnoea in 26.19% rats.

The frequency of symptoms at different doses of paraoxon was not significant, except in the case of piloerection, where it occurred after doses of paraoxon 0.2, 0.3, 0.35 and 0.4 mg/kg in 0%, 33.33%, 66.67% and 75.00%, respectively (χ² = 11,667, p = 0.009). The onset rate of poisoning clinical signs at different doses of paraoxon is shown in Table 1.

| Sign (ToO)       | Paraoxon dose (mg/kg sc) | p value |
|------------------|--------------------------|---------|
|                  | 0.2                      | 0.3     | 0.35 | 0.4     |
| Fasciculations   | 35.67 ± 17.95            | 34.25 ± 22.17 | 20.83 ± 1.84 | 12.70 ± 5.08 | 0.015* |
| Tremor           | 24.60 ± 7.92             | 19.33 ± 14.18 | 19.67 ± 31.29 | 7.67 ± 1.83 | 0.002* |
| Seizures         | 35.25 ± 20.81            | 24.78 ± 25.67 | 18.10 ± 18.73 | 10.42 ± 3.23 | 0.021* |
| Ataxia           | 47.60 ± 28.02            | 41.43 ± 51.82 | 33.89 ± 63.30 | 9.43 ± 3.10 | 0.016* |
| Piloerection     | -                        | 6.50 ± 3.32 | 7.75 ± 6.23 | 7.00 ± 2.83 | 0.972* |
| Exophthalmos     | 7.00 ± 3.46              | 5.82 ± 3.63 | 6.67 ± 3.75 | 3.92 ± 2.07 | 0.120* |
| Lacrimation      | 28.60 ± 24.34            | 39.50 ± 27.5 | 19.67 ± 9.58 | 17.00 ± 9.74 | 0.412* |
| Dyspnoea         | 29.50 ± 4.95             | 22.75 ± 12.53 | 27.33 ± 24.85 | 15.00 ± 7.07 | 0.795** |

ToO – time of occurrence (minutes after application of paraoxon)
* Kruskal-Wallis test, **One-Way ANOVA, Red colour – statistically significant
Values: mean ± standard deviation
### Table 2. Intensity of clinical signs of poisoning 15 min and 4 h after administration of increasing doses of paraoxon

| Sign (Intensity) | Paraoxon dose (mg/kg sc) | p value* |
|----------------|--------------------------|---------|
|                | 0.2                      | 0.3     | 0.35 | 0.4          |
| Fasciculations |                          |         |      |               |
| 15<sup>th</sup> min | 0 | 0.45 ± 0.82 | 0.58 ± 0.67 | 1.11 ± 0.93 | 0.052 |
| 240<sup>th</sup> min | 0.33 ± 0.52 | 0.56 ± 0.52 | 0.56 ± 0.73 | 2.00 ± 0.00 | 0.061 |
| Tremor         |                          |         |      |               |
| 15<sup>th</sup> min | 0.33 ± 0.52 | 0.82 ± 0.87 | 1.50 ± 0.67 | 1.78 ± 0.44 | 0.002 |
| 240<sup>th</sup> min | 0.17 ± 0.41 | 0.56 ± 0.53 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.044 |
| Seizures       |                          |         |      |               |
| 15<sup>th</sup> min | 0 | 0.91 ± 0.94 | 0.92 ± 0.79 | 1.67 ± 0.50 | 0.004 |
| 240<sup>th</sup> min | 0 | 0.11 ± 0.33 | 0.40 ± 0.55 | 1.00 ± 0.00 | 0.069 |
| Ataxia         |                          |         |      |               |
| 15<sup>th</sup> min | 0 | 0.45 ± 0.69 | 0.33 ± 0.49 | 0.44 ± 0.52 | 0.329 |
| 240<sup>th</sup> min | 0.33 ± 0.52 | 0.44 ± 0.88 | 1.00 ± 0.71 | 1.00 ± 0.00 | 0.271 |
| Piloerection   |                          |         |      |               |
| 15<sup>th</sup> min | 0 | 0.27 ± 0.47 | 0.83 ± 0.72 | 0.67 ± 0.50 | 0.016 |
| 240<sup>th</sup> min | 0 | 0 | 0 | 0 | - |
| Exophthalmos   |                          |         |      |               |
| 15<sup>th</sup> min | 1.00 ± 0.63 | 1.09 ± 0.53 | 1.50 ± 0.52 | 1.67 ± 0.50 | 0.055 |
| 240<sup>th</sup> min | 1.17 ± 0.98 | 1.22 ± 0.67 | 1.40 ± 0.55 | 2.00 ± 0.00 | 0.721 |

*Kruskal-Wallis test, Red colour – statistically significant. Values: mean ± standard deviation (Intensity: 0 - absent, 1 - mild/moderate, 2 - severe)

Bizzare-stereotypic behaviour, although frequent (69.05% of all animals), was not significantly different in either the intensity or the rate of sign on any parameter (data not shown).

Fasciculation, tremor, seizures, and ataxia occurred significantly earlier at higher doses of paraoxon. The intensity of signs measured 15 min and 4 h after paraoxon application relative to the dose applied is shown in Table 2.

The time-point of 15th minute was taken as the time period when most of the signs of poisoning were manifested, yet most of the rats were still alive, and the time period of 4th hour was taken as the end of the observation period.

In the presented time intervals (15 min and 4 h after paraoxon), the intensity of seizures, tremor and fasciculations increased significantly with increasing doses.
Piloerection was significantly higher at higher doses at the 15th min, however, it disappeared in all rats 45 min after poisoning.

To analyse the intensity of symptoms throughout the observed period (4 h), ToxScore was introduced, as a sum of the intensity of each sign in all time intervals. A significant difference was found in ToxScore values relative to dose regarding fasciculations and seizures (Figure 1). Other parameters were not significant.

TotToxScore is a measure that represents the sum of all ToxScores for one animal. TotToxScore values are shown in Figure 2.

Although the difference was not statistically significant, an increase in the value of TotToxScore is noticeable, as a joint parameter of the intensity and duration of signs of poisoning, especially at high doses.

b) Survival

Analysing the frequency of clinical signs in relation to whether the rat survived or not, a significant difference was found regarding the piloerection: 23.81% of survivors and 76.19% of non-survivors had piloerection ($\chi^2 = 11.524, p = 0.002$). The same goes for seizure frequency (66.67% in survivors vs 100.00% in non-survivors have had seizures, $\chi^2 = 8.400, p = 0.009$). The speed of onset of clinical signs of poisoning relative to whether or not the animals survived is shown in Table 3. All signs of poisoning occurred earlier in non-survivors compared to survivors.

### Table 3. Onset rate of clinical signs of paraoxon poisoning in relation to whether rats survived or not

| Sign (ToO)            | Survived   | p-value* |
|-----------------------|------------|----------|
|                       | Yes        | No       |          |
| Fasciculations        | 35.44 ± 16.94 | 12.61 ± 4.25 | <0.001* |
| Tremor                | 26.40 ± 24.02 | 7.38 ± 1.91 | <0.001* |
| Seizures              | 33.14 ± 23.74 | 9.81 ± 3.12 | <0.001* |
| Ataxia                | 52.33 ± 55.77 | 8.77 ± 2.05 | <0.001* |
| Piloerection          | 8.40 ± 5.64  | 6.81 ± 3.97 | 0.646*  |
| Exophthalmos          | 6.60 ± 3.35  | 4.70 ± 3.16 | 0.025*  |
| Lacrimation           | 32.33 ± 22.28 | 14.37 ± 6.59 | 0.086*  |
| Dyspnoea              | 33.67 ± 11.18 | 12.00 ± 5.83 | 0.004** |

ToO – time of occurrence (minutes after application of paraoxon)

*Man-Whitney U-test, ** Student t-test, Red colour – statistically significant

Values: mean ± standard deviation
Table 4. Signs intensity at 15 min after paraoxon administration in relation to whether the rat survived or not

| Sign (Intensity) | Survived |  |  |  | p-value* |
|-----------------|----------|---|---|---|---------|
|                 | Yes      | No |  |   |         |
| Fasciculations  | 0.09 ± 0.44 | 1.17 ± 0.73 |  |   | <0.001  |
| Tremor          | 0.71 ± 0.78 | 1.76 ± 0.44 |  |   | <0.001  |
| Seizures        | 0.43 ± 0.75 | 1.59 ± 0.51 |  |   | <0.001  |
| Ataxia          | 0.19 ± 0.40 | 0.53 ± 0.62  |  |   | 0.059   |
| Piloerection    | 0.19 ± 0.40 | 0.88 ± 0.60  |  |   | 0.646   |
| Exophthalmos    | 1.14 ± 0.48 | 1.59 ± 0.62  |  |   | 0.011   |
| Lacrimation     | 0.33 ± 0.48 | 0.18 ± 0.39  |  |   | 0.416   |
| Dyspnoea        | 0.24 ± 0.56 | 0.00 ± 0.00  |  |   | 0.048   |

* Man-Whitney U-test, Red colour – statistically significant. Values: mean ± standard deviation (Intensity: 0- absent, 1- mild/moderate, 2- severe)

Table 5. Onset rate of clinical signs of poisoning at different doses of paraoxon with atropine protection (10 mg/kg im) (one minute after application of paraoxon)

| Sign (ToO)       | Paraoxon dose (mg/kg sc) |  |   |  | p-value |
|------------------|--------------------------|---|---|---|---------|
|                  | 0.6 | 0.9 | 1.2 |  |         |
| Fasciculations   | 28.83 ± 30.75 | 7.60 ± 1.95 | 10.33 ± 4.73 |  | 0.038*  |
| Tremor           | 12.83 ± 5.85 | 8.33 ± 1.03 | 5.00 ± 2.19  |  | 0.007*  |
| Seizures         | 18.20 ± 15.21 | 9.50 ± 1.64 | 8.50 ± 4.64  |  | 0.170** |
| Ataxia           | 51.50 ± 79.20 | 8.00 ± 2.83 | 70.50 ± 85.56 |  | 0.444*  |
| Piloerection     | 4.33 ± 1.15  | 6.00 ± 3.60 | 5.17 ± 2.56  |  | 0.507*  |
| Exophthalmos     | 3.20 ± 1.64  | 4.00 ± 2.89 | 6.00 ± 0.89  |  | 0.134*  |
| Lacrimation      | 111.00 ± 0.00 | 105.00 ± 140.00 | 6.00 ± 0.00 |  | 0.632*  |
| Dyspnoea         | 63.40 ± 46.47 | 25.33 ± 31.77 | 52.50 ± 44.55 |  | 0.504** |

ToO – time of occurrence (minutes after application of paraoxon)

* Kruskal-Wallis test, **One-Way ANOVA. Red colour – statistically significantValues: mean ± standard deviation

The intensity of the signs at 15 min after paraoxon application in relation to whether the rat survived or not is shown in Table 4. Apart from lacrimation and stereotypy, all other signs were of higher intensity in non-survivors.

The most significant difference in intensity was recorded in fasciculations, tremor and seizures, where high significance was found (p < 0.001).
**Paraoxon and atropine**

**a) Dose**

The PR of atropine was 2.73 (LD$_{50}$ of paraoxon when atropine was administered 1 min after was 0.91 mg/kg sc (95% CI: 0.67 - 1.25)). In all rats, death occurred during the first hour of poisoning (mean ± SD: 14.00 ± 3.74, 95% CI: 10.87 - 17.13).

Fasciculations occurred in 77.78% of all rats, piloerection in 33.33%, exophthalmos in 94.44%, lacrimation in 22.22%, tremor in 100.00%, seizures in 94.44%, ataxia in 44.44%, stereotypic behaviour in 38.89% and dyspnoea in 55.56% of rats.

In atropine-protected rats, the dose had a significantly smaller effect on the speed and frequency of symptoms. The frequency of any poisoning signs was not affected by the dose.

As for the onset of clinical signs manifestation, a significant difference was found only in fasciculations ($p = 0.038$) and tremor ($p = 0.007$) (Table 5).

The intensity of the signs persisted throughout the observation period. The intensities of certain symptoms at 15th min and after 4 h relative to the dose are shown in Table 6.

---

**Table 6. Intensity of clinical signs of poisoning 15 min and 4 h after the application of paraoxon and atropine (10 mg/kg, im, one minute after) depending on the dose of paraoxon**

| Sign (Intensity) | Paraoxon dose (mg/kg sc) | p-value* |
|-----------------|--------------------------|----------|
|                 | 0.6 | 0.9 | 1.2 |
| Fasciculations  |     |     |     |
| 15th min        | 0.89 ± 0.37 | 0.71 ± 0.32 | 0.55 ± 0.24 | 0.613 |
| 240th min       | 1.00 ± 0.00 | 1.00 ± 0.00 | 2.00 ± 0.00 | 0.011 |
| Tremor          |     |     |     |
| 15th min        | 1.17 ± 0.41 | 2.00 ± 0.00 | 1.8 ± 0.45 | 0.015 |
| 240th min       | 0.67 ± 0.52 | 1.00 ± 0.00 | 1.00 ± 0.00 | 0.472 |
| Seizures        |     |     |     |
| 15th min        | 0.83 ± 0.98 | 2.00 ± 0.00 | 2.00 ± 0.00 | 0.017 |
| 240th min       | 0    | 0.50 ± 0.71 | 2.00 ± 0.00 | 0.022 |
| Ataxia          |     |     |     |
| 15th min        | 0.33 ± 0.52 | 0.40 ± 0.55 | 0.20 ± 0.45 | 0.797 |
| 240th min       | 0.33 ± 0.52 | 0.50 ± 0.71 | 2.00 ± 0.00 | 0.073 |
| Dyspnoea        |     |     |     |
| 15th min        | 0.17 ± 0.41 | 0.20 ± 0.45 | 0.40 ± 0.89 | 0.961 |
| 240th min       | 0.33 ± 0.52 | 0.50 ± 0.71 | 1.00 ± 0.00 | 0.301 |

Kruskal-Wallis test, Red colour – statistically significant. Values: mean ± standard deviation (Intensity: 0 - absent, 1 - mild/moderate, 2 - severe)
The cross-section at the 15th minute was taken as the time period when most of the signs of poisoning were present, yet most of the rats were still alive, while the 4th h was taken as the end of the observation period.

Figure 3.
Dose-dependent ToxScore (paraoxon with atropine protection)
*Kruskal-Wallis test; ToxScore: the sum of the values of each sign in each point of time

ToxScore, although without statistical significance, showed a clear increase in fasciculations, tremor, seizures, ataxia, and dyspnoea with increasing doses of paraoxon (Figure 3).

TotToxScore values for paraoxon poisoning followed by atropine administration are shown in Figure 4.

Figure 4.
Mean TotToxScore relative to dose of paraoxon with atropine protection
*TotToxScore: the sum of the values of all sign in each point of time; Kruskal-Wallis test

Total Tox Score, although without statistical significance, showed a clear increase with higher dose.

b) Survival

There was no significant difference in the frequency of symptoms in relation to whether the rat survived or not. It was only observed that ataxia was more common in survivors than in non-survivors (70.00% vs 12.50%, respectively; \( \chi^2 = 5.591, p = 0.025 \)) as well as fasciculations (100.00% vs 50.00%, respectively; \( \chi^2 = 6.429, p = 0.023 \)).

A significant difference in the onset of symptoms relative to whether or not a rat survived was observed only regarding fasciculations. The onset rate of poisoning clinical signs relative to whether or not the animals survived is shown in Table 7.

Table 7. Onset rate of clinical signs of paraoxon poisoning with atropine administration in relation to whether rats survived or not

| Sign (ToO)   | Survived     | P-value* |
|--------------|--------------|----------|
| Fasciculations | 21.70 ± 24.76 | 6.25 ± 0.96 | 0.004* |
| Tremor       | 10.50 ± 5.58 | 6.50 ± 2.50 | 0.083* |
| Seizures     | 14.67 ± 11.72| 8.38 ± 3.42 | 0.117**|
| Ataxia       | 50.43 ± 69.43| 10.00 ± 0.00| -      |
| Piloerection | 5.00 ± 1.63  | 5.50 ± 4.95 | -      |
| Exophtalmus  | 4.22 ± 1.86  | 4.75 ± 2.71 | 0.673* |
| Lacrimation  | 157.50 ± 65.76| 6.00 ± 0.00 | 0.333* |
| Dyspnoea     | 60.50 ± 39.27| 7.00 ± 1.41 | 0.098**|

ToO – time of occurrence (minutes after application of paraoxon). Red colour – statistically significant; *Man-Whitney U-test; ** Student t-test; Values: mean ± standard deviation

Most signs of poisoning occurred earlier in non-survivors, but statistical significance was found only regarding fasciculations (p = 0.004).
The intensity of any signs of poisoning did not differ significantly in survivors and non-survivors (Table 8).

**DISCUSSION**

Paraoxon is one of the most toxic OPIs and is therefore banned from use as an insecticide in most countries. The obtained LD_{50} of paraoxon was 0.33 mg/kg sc, which roughly corresponds to the data from the literature [16]. Death in almost all animals occurs in the first two hours of OP poisoning, which is consistent with the data obtained in this study [17].

The LD_{50} of paraoxon, when 10 mg/kg of atropine is administered after 1 minute, was 0.91, so the PR of atropine was 2.73, similar to the data in the literature [18]. Atropine is used as an antidote for poisoning with AChE inhibitors. It is much more effective in carbamate poisoning than in those caused by OPs [18]. It is logical that PR will be significantly higher in carbamates than OP poisoning given that carbamates are reversible AChE inhibitors, so the spontaneous reactivation of AChE makes the task of atropine as an antidote less demanding [19][20][21]. Considering the dose of atropine, 10 mg/kg im was selected because it is the most frequently used dose; therefore the results obtained in this experiments are comparable to the results of other researchers [22]. Krutak-Kol and Domino tried different doses of atropine against paraoxon poisoning: 10, 33 and 100 mg/kg and found that higher doses did not increase survival. Moreover, a dose of 100 mg/kg was significantly less effective than the dose of 10 mg/kg [23]. Repeated lower doses of atropine over time might potentially give better results [24].

The presence, time of occurrence and intensity of paraoxon poisoning signs were examined. The same parameters of poisoning were also observed at high lethal doses of paraoxon, in animals given atropine. Those signs that can be noticed only by observation without manipulation of the animal were analysed.

Lacrimation occurs by excessive stimulation of muscarinic receptors. Although not life-threatening, it can serve as a good indicator of muscarinic excitation, as well as sign of adequate atropinisation during treatment [33]. Neither the intensity nor the rate of lacrimation occurred statistically significantly at different doses of paraoxon and in relation to the survival rate. However, when atropine was administered after paraoxon, lacrimation was significantly less common and occurred later, although significantly higher doses of paraoxon were administered (only 22% vs 55% when atropine was not administered). Regardless of the dose, the results obtained were expected since it is well known that atropine is an anti-muscarinic drug. The existence of lacrimation can indirectly indicate that there are other effects of muscarinic excitation (hypotension, bradycardia).

Muscarinic effects that are directly life-threatening are bronchoconstriction and bronchorrhoea. Dyspnoea was monitored as a parameter indicating respiratory failure, which in studies by other researchers proved to be the main cause of lethality in OPI poisoning [25][26][27]. The disadvantage of this study is that dyspnoea was only subjectively observed, without objective measuring of respiratory failure degree. Sometimes, in severe seizures dyspnoea could be noticed only when the intensity of seizures subsided. Nevertheless, a clear link was found in the intensity and speed of occurrence of dyspnoea in relation to whether the animal survived or not. In animals treated with atropine after paraoxon administration, atropine delayed and reduced the intensity of dyspnoea, although these were significantly higher doses of paraoxon. Houze et al analysed whether respiratory failure in OP poisoning was due to central or peripheral muscarinic effects [28]. He showed that respiratory failure was almost completely corrected by atropine and not corrected at all by 100 times the equimolar dose of N-methylatropine and concluded that respiratory failure is due to central muscarinic effects. On the other hand, Villa et al found that

| Sign (Intensity) | Survived | p-value* |
|-----------------|----------|----------|
|                 | Yes      | No       |          |
| Fasciculations  | 1.10 ± 0.74 | 0.50 ± 0.55 | 0.147   |
| Tremor          | 1.50 ± 0.53 | 1.83 ± 0.41 | 0.313   |
| Seizures        | 1.30 ± 0.95 | 2.00 ± 0.00 | 0.220   |
| Ataxia          | 0.40 ± 0.52 | 0.17 ± 0.41 | 0.492   |
| Piloerection    | 0.10 ± 0.32 | 0.17 ± 0.41 | 0.875   |
| Exophthalmos    | 0.80 ± 0.42 | 1.00 ± 0.63 | 0.635   |
| Dyspnoea        | 0.30 ± 0.67 | 0.17 ± 0.41 | 0.875   |

* Man Whitney U-test; Values: mean ± standard deviation (Intensity: 0 - absent, 1 - mild/moderate, 2 - severe)
50% and 75% of LD50 paraoxon caused alterations in ventilation, but did not cause respiratory failure [29]. Fasciculations were a sign that, along with seizures, proved to be the most consistent parameter of the poisoning severity. Fasciculations occurred faster and were of higher intensity when the dose of paraoxon as well as survival of rats was observed. This can be explained by the fact that among the examined signs, fasciculations are those that follow overstimulation of nicotinic receptors on the neuromuscular junction. If it is assumed that according to the Poison Severity Score (PSS) in humans, any occurrence of nicotine sings of poisoning is considered at minimum as moderate poisoning, then it can be concluded that fasciculations, as a parameter of nicotine effects of poisoning, directly indicates the severity of poisoning [30]. An additional problem is lack of effective antidote that would function as a nicotine antagonist, without serious side effects [31][32]. As expected, atropine administration did not affect the rate and intensity of fasciculations - they were of higher intensity and occurred earlier, because the dose of paraoxon was higher.

Muscle tremor was also a sign of inappropriate stimulation of nicotinic receptors on the neuromuscular joint, ie weakness of skeletal muscles. Tremor has been more often described in the literature as part of the delayed onset of extrapyramidal syndrome, rather than acute OP poisoning sign [33]. Since the monitoring of poisoning signs was based on observation, tremor served as a good indicator of muscle weakness. A strong relationship was found between both the speed of onset and the intensity of tremor, and the dose of paraoxon or the lethal outcome in rats. As expected, the results did not change when atropine was given after paraoxon, but the tremor occurred earlier and was of stronger intensity at higher doses and in non-survivors.

ACh is also found in the preganglionic fibres of the sympathetic nervous system. Piloerection is a sign that occurs as a consequence of excessive stimulation of preganglionic nicotinic receptors of the sympathetic nervous system [34]. Therefore, piloerection can be considered as potential predictor of sympathetic stimulation. The results of this study showed a strong relationship between the dose of paraoxon and the frequency of piloerection. Studies from other researchers show that the incidence of tachycardia in OP poisoning is 35-60%, making it more common than bradycardia [35]. The alpha-1-adrenergic receptor, in addition to piloerection, in rats is also involved in retraction of the eyelids, leading to exophthalmos [36]. Unlike piloerection, exophthalmos remained most persistent throughout the observed period and had no statistical significance in the intensity and rate of exophthalmos in relation to paraoxon dose and rat mortality. The same results were obtained when atropine was administered after high doses of paraoxon.

Seizures initially occur due to stimulation of cholinergic receptors in the CNS and at this stage can be reversed by atropine. Prolonged seizure activity is due to excessive release of glutamate, when atropine is not effective [37]. For now, seizures are treated with combinations of anticholinergics and benzodiazepines but, given the role of glutamate in seizures, future therapies should include N-methyl-D-aspartate receptor (NMDA) antagonists [38]. The rate and intensity of seizures were clearly correlated to dose and especially to death in paraoxon poisoning. Seizures occur significantly less frequently in OPI than in nerve agents [39]. In this study, seizures occurred in 83% of rats and 100% of non-survivors, which additionally contribute to the characteristics of paraoxon as a nerve agents. Administration of atropine somewhat postponed and decreased the intensity of seizures. There was still a clear relationship between these parameters and paraoxon dose as well as fatal outcome, but seizures occurred later and were less intense than would be expected, given the paraoxon doses administered.

Ataxia is caused by stimulation of muscarinic receptors in the CNS. In addition, in acute OP poisoning, ataxia occurs as a consequence of muscle fatigue, but ataxia is more intense than would be expected from muscle fatigue alone [40]. The results of this study show that ataxia occurred earlier at higher doses of paraoxon and in non-surviving rats.

ToxScore and TotToxScore are parameters that were introduced in order to see the persistence of symptoms related to the dose. Thus, the values of each sign in each point of time were summed, which made up the ToxScore, and the values of all ToxScores were added to calculate the TotToxScore for each animal. The pre-condition is that the animal survived the observation period. These parameters can also be used in future studies, when the protective effect of antidotes (either individually or in combination) can be compared, not only as a measure of survival, but also their ability to alleviate the signs of poisoning. ToxScore showed that the same parameters (seizure, fasciculation, tremor) that were significant indicators of the severity of poisoning lasted longer at higher doses. The TotToxScore had higher value at higher dose and, although the difference was not significant, showed a clear trend.
CONCLUSION

Seizures and fasciculations followed by tremor were strong prognostic parameters of the probability of lethal outcome of paraoxon poisoning. Also, the mentioned signs of poisoning were with their intensity and speed of occurrence in a clear correlation with the dose of paraoxon. Even at high doses of paraoxon, atropine blocked the muscarinic (but not nicotinic) effects, and somewhat mitigated the CNS effects.

Acknowledgements

This work was funded by the Ministry of Scientific and Technological Development, Higher Education and Information Society of the Government of the Republic of Srpska (Grant No 125 7030).

Conflict of interest

None.

REFERENCES

1. Adeyinka A, Muco E, Pierre L. Organophosphates. [Internet]. Treasure Island, FL: StatPearls Publishing. 2020 [cited Aug 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499860/.

2. Pope CN, Brimijoin S. Cholinesterases and the fine line between poison and remedy. Biochem Pharmacol. 2018;153:205-216. [Crossref] [PubMed] [PMC] [Google Scholar]

3. Eddleston M. Novel clinical toxicology and pharmacology of organophosphorus insecticide self-poisoning. Annu Rev Pharm Toxicol. 2019;59(1):341-360. [Crossref] [Google Scholar]

4. Reddy BS, Skaria TG, Polepalli S, Vidyasagar S, Rao M, Kunhikatta V, et al. Factors associated with outcomes in organophosphate and carbamate poisoning: A retrospective study. Toxicol Res. 2020;36(3):257-266. [Crossref] [PubMed] [PMC] [Google Scholar]

5. Jokanović M, Stojiljković MP, Kovač B, Ristić D. Pyridinium oximes in the treatment of poisoning with organophosphorus compounds. In: Gupta RC, editor(s). Handbook of chemistry of chemical warfare agents. Cambridge, MA: Elsevier - Academic Press. 2020; p. 1145-1159. [Crossref] [Google Scholar]

6. Worek F, Thiemann H, Wille T. Organophosphorus compounds and oximes: A critical review. Arch Toxicol. 2020;94(7):2275-2292. [Crossref] [PubMed] [PMC] [Google Scholar]

7. Antonijević B, Stojiljković MP. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res. 2007;5(1):71-82. [Crossref] [PubMed] [PMC] [Google Scholar]

8. Vanova N, Pejchal J, Herman D, Dlabkova A, Jun D. Oxidative stress in organophosphate poisoning: Role of standard antidotal therapy. J Appl Toxicol. 2018;38(8):1058-1070. [Crossref] [Google Scholar]

9. Henretig FM, Kirk MA, McKay CAJ. Hazardous chemical emergencies and poisonings. N Engl J Med. 2019;380(17):1638-1655. [Crossref] [Google Scholar]

10. Amir A, Raza A, Qureshi T, Mahesar GB, Jafferi S, Haleem F, et al. Organophosphate poisoning: Demographics, severity scores and outcomes from National Poisoning Control Centre, Karachi. Cureus. 2020;12(5). [Crossref] [PubMed] [PMC] [Google Scholar]

11. Kaushal J, Khatri M, Arya SK. A treatise on Organophosphate pesticide pollution: Current strategies and advancements in their environmental degradation and elimination. Ecotoxicol Environ Saf. 2021;207. [Crossref] [Google Scholar]

12. WHO (Geneva). Health topics: mental health [Internet]. [cited 2020-Dec-30]. Available from: https://www.who.int/mental_health/prevention/suicide/en/PesticidesHealth2.pdf.

13. Stojiljković MP. Nerve agents: A clear and present danger to mankind. Scripta Medica. 2019;50(3):109-111. [Crossref] [Google Scholar]

14. Misik J, Pavlikova R, Cabal J, Kuca K. Acute toxicity of some nerve agents and pesticides in rats. Drug Chem Toxicol. 2015;38(1):32-36. [Crossref] [Google Scholar]

15. Kassa J, Misik J, Hatlapatkova J, Zdárova KJ, Sepsova V, Caisberger F, et al. The evaluation of the reactivating and neuroprotective efficacy of two newly prepared bispyridinium oximes (K305, K307) in tabun-poisoned rats: A comparison with trimedoxime and the oxime K203. Molecules. 2017;22(7):1152-1152. [Crossref] [PubMed] [PMC] [Google Scholar]

16. Holmstedt B. Pharmacology of organophosphorus cholinesterase inhibitors. Pharmacol Rev. 1959(11):567-688. [Google Scholar]

17. Stojiljković MP, Škrbić R, Jokanović M, Kilibarda V, Vukonić D, Vulović M, et al. Efficacy of antidotes and their combinations in the treatment of acute carbamate poisoning in rats. Toxicology. 2018;408:113-124. [Crossref] [Google Scholar]

18. Natoff IL, Reiff B. Effect of oximes on the acute toxicity of anticholinesterase carbamates. Toxicol Appl Pharmacol. 1973;124(5):569-575. [Crossref] [Google Scholar]

19. Kords H, Lüllmann H, Ohnesorge FK, Wassermann O. Action of atropine and some hexane-1.6-bis-ammonium derivatives upon the toxicity of DFP in mice. Eur J Pharmacol. 1968;3(4):341-346. [Crossref] [Google Scholar]

20. Albuquerque EX, Pereira EFR, Aracava Y, Fawcett WP, Oliveira M, Randall WR, et al. Effective countermeasure
against poisoning by organophosphorus insecticides and nerve agents. Proc Natl Acad Sci U S A. 2006;103(35):13220-13225. [Crossref] [PubMed] [PMC] [Google Scholar]

23. Parkes MW, Sacra P. Protection against the toxicity of cholinesterase inhibitors by acetylcholine antagonists. Br J Pharmacol Chemother. 1954;9(3):299-305. [Crossref] [PubMed] [PMC] [Google Scholar]

24. Krutak-Krol H, Domino EF. Comparative effects of Diazepam and midazolam on paraoxon toxicity in rats. Toxicol Appl Pharmacol. 1985;81(3 Pt 1):545-50. [Crossref] [Google Scholar]

25. Rump S, Faff J, Szymańska T, Bąk W, Borkowska G. Efficacy of repeated pharmacotherapy in experimental acute poisonings with fluostigmine. Arch Toxicol. 1976;35(4):275-280. [Crossref] [Google Scholar]

26. Eddleston M, Eyer P, Worek F, Mohamed F, Senarathna L, von Meyer L, et al. Differences between organophosphorus insecticides in human self-poisoning: A prospective cohort study. Lancet. 2005;366(9495):1452-1459. [Crossref] [Google Scholar]

27. Namba T, Nolte CT, Jackrel J, Grob D. Poisoning due to organophosphate insecticides: Acute and chronic manifestations. Am J Med. 1971;50(4):475-92. [Crossref] [PubMed] [Google Scholar]

28. Ballantyne B, Marrs TC. Overview of the biological and clinical aspects of organophosphates and carbamates. In: Ballantyne B, Marrs TC, editor(s). Clinical and experimental toxicology of organophosphates and carbamates. Oxford: Elsevier - Butterworth-Heinemann. 1992; p. 3-14. [Crossref] [Google Scholar]

29. Houze P, Pronzola L, Kayouka M, Villa A, Debray M, Baud FJ, et al. Ventilatory effects of low-dose paraoxon result from central muscarinic effects. Toxicol Appl Pharmacol. 2008;233(2):186-192. [Crossref] [Google Scholar]

30. Villa AF, Houze P, Monier C, Risède P, Sarhan H, Borron SW, et al. Toxic doses of paraoxon alter the respiratory pattern without causing respiratory failure in rats. Toxicology. 2007;232(1-2):37-49. [Crossref] [Google Scholar]

31. Persson HE, Sjöberg GK, Haines JA, de Garbino JP. Poisoning severity score: Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36(3):205-213. [Crossref] [Google Scholar]